IP Library Granted Patent US 11,446,368
Granted Patent B2
US 11,446,368 · App. 16/997,307 · Granted Sep 20, 2022

Vaccine comprising epitope of heat shock protein, and use thereof

Inventors: Kyong Hwa Park (Seoul, KR); Jinho Kang (Seoul, KR)
Assignee: ASTON SCI. CO., LTD.
A61K39/001176C07K16/18G01N33/57484A61K39/39A61K45/06C07K2317/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,446,368
App. No.
16/997,307
Granted
Sep 20, 2022
Kind
B2
Abstract

A vaccine containing an epitope of a heat shock protein 90 and uses thereof are disclosed. The epitope(s) of heat shock protein 90 has the amino acid sequence of SEQ ID NO: 1 and/or 2. A multi-epitope vaccine containing the epitope(s) and a method for treating or preventing cancer using the same are disclosed.

Claims (13)

1. A multi-epitope vaccine comprising an adjuvant and a mixture of two different MHC class II-specific epitopes from a heat shock protein 90 (HSP90), wherein said two MHC class II-specific epitopes consisting of the amino acid sequence of SEQ ID NO: 1 and the amino acid sequence of SEQ ID NO: 2.

2. The multi-epitope vaccine according to claim 1 , which induces production of an antibody and/or activation of immune cells that recognizes heat shock protein 90 as an antigen.

3. A multi-epitope vaccine comprising an adjuvant and nucleic acid molecules encoding the two MHC class II-specific epitopes, as described in claim 1 .

4. A vaccine composition comprising the vaccine of claim 1 .

5. The composition according to claim 4 , further comprising STING (Stimulator of Interferon gene) agonist.

6. The composition according to claim 5 , further comprising an immune checkpoint inhibitor against any one selected from the group consisting of CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), PD-1 (Programmed cell death protein 1), LAG-3 (Lymphocyte Activation Gene-3), TIM-3 (T-cell Immunoglobulin and Mucin-domain containing-3), TIGIT (T-cell Immunoreceptor with IG and ITIM domain), and VISTA (V-domain Ig Suppressor of T cell Activation).

7. A method of administering the vaccine of claim 1 comprising administering an effective amount of the vaccine to produce an antibody binding a heat shock protein 90.

8. A composition comprising an adjuvant and an isolated heat shock protein 90 (HSP90)-specific MHC class II epitope, wherein the epitope consists of a peptide selected from a group consisting of SEQ ID NOs: 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14.

9. A method for manufacturing the multi-epitope vaccine of claim 1 , comprising the step of synthesizing SEQ ID NO: 1 and SEQ ID NO: 2 that induces production of antibodies.

10. A method for manufacturing the composition of claim 8 , comprising the step of synthesizing a peptide selected from SEQ ID NOs: 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14.

11. A vaccine composition comprising the vaccine of claim 3 .

12. A method of administering the vaccine of claim 3 comprising administering an effective amount of the vaccine to produce an antibody binding a heat shock protein 90.

13. A composition comprising an adjuvant and a nucleic acid molecule encoding an epitope consisting of a peptide selected from a group consisting of SEQ ID NOs: 1, 2, 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2022
From: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATIO
To: ASTON SCI. CO., LTD.
Reel/Frame 058584/0331 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2020
From: PARK, KYONG HWA; KANG, JINHO
To: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
Reel/Frame 054538/0028 →
Priority Claims (2)
KR 10-2018-0019123 · Feb 19, 2018 · national
KR 10-2019-0018119 · Feb 15, 2019 · national
Continuity (2)
Continuation In Part PCTKR2019001898 · Feb 18, 2019
Related Publication 20200376105A1 · Dec 3, 2020